Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health

Antoine Vanier; Judith Fernandez; Sophie Kelley; Lise Alter; Patrick Semenzato; Corinne Alberti; Sylvie Chevret; Dominique Costagliola; Michel Cucherat; Bruno Falissard; François Gueyffier; Jérôme Lambert; Etienne Lengliné; Clara Locher; Florian Naudet; Raphael Porcher; Rodolphe Thiébaut; Muriel Vray; Sarah Zohar; Pierre Cochat; Dominique Le Guludec

doi:10.1136/bmjebm-2022-112091

Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health

BMJ Evid Based Med. 2024 Jan 19;29(1):1-5. doi: 10.1136/bmjebm-2022-112091.

Authors

Antoine Vanier^{1

2}, Judith Fernandez³, Sophie Kelley³, Lise Alter³, Patrick Semenzato³, Corinne Alberti^{4

5}, Sylvie Chevret⁶, Dominique Costagliola⁷, Michel Cucherat⁸, Bruno Falissard⁹, François Gueyffier¹⁰, Jérôme Lambert⁶, Etienne Lengliné¹¹, Clara Locher¹², Florian Naudet^{13

14}, Raphael Porcher¹⁵, Rodolphe Thiébaut¹⁶, Muriel Vray¹⁷, Sarah Zohar^{18

19}, Pierre Cochat²⁰, Dominique Le Guludec²⁰

Affiliations

¹ Health Technology Assessment Department, Haute Autorité de Santé, La Plaine Saint-Denis, France a.vanier@has-sante.fr.
² UMR U1246 Sphere, Inserm - Nantes Université - Université de Tours, Nantes, France.
³ Health Technology Assessment Department, Haute Autorité de Santé, La Plaine Saint-Denis, France.
⁴ ECEVE, Inserm - Université Paris Cité, Paris, France.
⁵ CIC 1426, UEC, Inserm - AP-HP Robert-Debré Mother-Child University Hospital, Paris, France.
⁶ UMR U1153 - ECSTRRA Team, Inserm - Université Paris Cité, Paris, France.
⁷ Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Inserm - Sorbonne Universite, Paris, France.
⁸ Pharmacology Department, Université Claude Bernard Lyon 1, Villeurbanne, France.
⁹ UMR U1018 CESP, Inserm - UVSQ - AP-HP - Université Paris-Saclay, Paris, France.
¹⁰ Pôle de Santé Publique - Unité des Bases de Données Cliniques et Epidemiologiques, Hospices Civils de Lyon, Lyon, France.
¹¹ Hematology Department, AP-HP Hopital Saint-Louis, Paris, France.
¹² CIC 1414 - Service de Pharmacologie Clinique - Irset UMR S1085, Inserm - CHU de Rennes - EHESP - Rennes 1 University, Rennes, France.
¹³ CIC 1414 - Irset UMR S1085, Inserm - CHU de Rennes - EHESP - Rennes 1 University, Rennes, France.
¹⁴ Institut Universitaire de France, Paris, France.
¹⁵ Centre de Recherche Epidémiologie et Statistiques (CRESS-UMR1153), Inserm - Université Paris Cité, Paris, France.
¹⁶ Bordeaux Population Health - SISTM - Service d'Information Médicale, Inserm - Inria - Bordeaux 1 University - CHU de Bordeaux, Bordeaux, France.
¹⁷ Unité d'Epidémiologie des Maladies Emergentes, Institut Pasteur - Inserm, Paris, France.
¹⁸ Centre de Recherche des Cordeliers, Inserm - Université Paris-Cité - Sorbonne Université, Paris, France.
¹⁹ HeKA, Inria, Paris, France.
²⁰ Scientific Board, Haute Autorité de Santé, La Plaine Saint-Denis, France.

No abstract available

Keywords: Drug Development; Health Care Economics and Organizations; Health Care Quality, Access, and Evaluation.

MeSH terms

Drug Industry*
Humans
Technology Assessment, Biomedical*